Different effects of simvastatin and losartan on cytokine levels in coronary artery disease

American Journal of Cardiovascular Drugs

Volumn 6, Issue 3, 2006, Pages 169-175

  Sadamatsu, Kenji ^a   Shimokawa, Hiroaki ^b   Tashiro, Hideki ^a   Seto, Taku ^a   Kakizoe, Hiroshi ^c   Yamamoto, Kunihiko ^a  

^a ST MARY S HOSPITAL   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c Kakizoe Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; COLONY STIMULATING FACTOR 1; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOSARTAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRATE; SIMVASTATIN; TRANSFORMING GROWTH FACTOR BETA;

AGED; ANALYSIS OF VARIANCE; ARTICLE; ATHEROGENESIS; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEMOGRAPHY; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; FEMALE; HUMAN; LONG TERM CARE; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BIOLOGICAL MARKERS; BLOOD PRESSURE; C-REACTIVE PROTEIN; CHOLESTEROL, LDL; CORONARY ARTERIOSCLEROSIS; CORONARY ARTERY DISEASE; CYTOKINES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOSARTAN; MACROPHAGE COLONY-STIMULATING FACTOR; MALE; MIDDLE AGED; SIMVASTATIN; TRANSFORMING GROWTH FACTOR BETA; TREATMENT OUTCOME;

EID: 33745494141     PISSN: 11753277     EISSN: 11753277     Source Type: Journal    
DOI: 10.2165/00129784-200606030-00004     Document Type: Article

References (36)

1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9
2. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals; a randomised placebo-controlled trial. Lancet 2002; 360: 7-22
3. Strawn WB, Chappell MC, Dean RH, et al. Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. Circulation 2000; 101: 1586-93
4. Usui M, Egashira K, Tomita H, et al. Important role of local angiotensin II activity mediated via type 1 receptor in the pathogenesis of cardiovascular inflammatory changes induced by chronic blockade of nitric oxide synthesis in rats. Circulation 2000; 101: 305-10
5. Kondo J, Sone T, Tsuboi H, et al. Effects of low-dose angiotensin II receptor blocker candesartan on cardiovascular events in patients. Am Heart J 2003; 146: E20
6. Tashiro H, Shimokawa H, Yamamoto K, et al. Altered plasma levels of cytokines in patients with ischemic heart disease. Coron Artery Dis 1997; 8: 143-7
7. Ikonomidis I, Andreotti F, Economou E, et al. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation 1999; 100: 793-8
8. Hojo Y, Ikeda U, Takahashi M, et al. Increased levels of monocyte-related cytokines in patients with unstable angina. Atherosclerosis 2002; 161: 403-8
9. Tashiro H, Shimokawa H, Sadamatsu K, et al. Role of cytokines in the pathogenesis of restenosis after percutaneous transluminal coronary angioplasty. Coron Artery Dis 2001; 12: 107-13
10. Saitoh T, Kishida H, Tsukada Y, et al. Clinical significance of increased plasma concentration of macrophage colony-stimulating factor in patients with angina pectoris. J Am Coll Cardiol 2000; 35: 655-65
11. Tashiro H, Shimokawa H, Sadamatu K, et al. Prognostic significance of plasma concentrations of transforming growth factor-β in patients with coronary artery disease. Coron Artery Dis 2002; 13: 139-43
12. Qiao JH, Tripathi J, Mishra NK, et al. Role of macrophage colony-stimulating factor in atherosclerosis: studies of osteopetrotic mice. Am J Pathol 1997; 150: 1687-99
13. Mozes G, Mohacsi T, Gloviczki P, et al. Adenovirus-mediated gene transfer of macrophage colony stimulating factor to the arterial wall in vivo. Arterioscler Thromb Vasc Biol 1998; 18: 1157-63
14. Sadamatsu K, Shimokawa H, Tashiro H, et al. Long term treatment with enalapril reduces plasma concentrations of macrophage colony stimulating factor in patients with coronary artery disease. Heart 2001; 86: 457-8
15. Caterina RD, Manes C. Inflammation in early atherogenesis: impact of ACE inhibition. Eur Heart J 2003; 5 Suppl. A: A15-24
16. Laufs U, Fata VL, Plutzky J, et al. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998; 97: 1129-35
17. Peng HB, Rajavashisth TB, Libby P, et al. Nitric oxide inhibits macrophage-colony stimulating factor gene transcription in vascular endothelial cells. J Biol Chem 1995; 270: 17050-5
18. Mallat Z, Gojova A, Marchiol-Fournigault C, et al. Inhibition of transforming growth factor-β signaling accelerates atherosclerosis and induces an unstable plaque phenotype in mice. Circ Res 2001; 89: 930-4
19. Lutgens E, Gijbels M, Smook M, et al. Transforming growth factor-β mediates balance between inflammation and fibrosis during plaque progression. Arterioscler Thromb Vasc Biol 2002; 22: 975-82
20. Cipollone F, Fazia M, Mincione G, et al. Increased expression of transforming growth factor-β1 as a stabilizing factor in human atherosclerotic plaques. Stroke 2004; 35: 2253-7
21. Satoh C, Fukuda N, Hu WY, et al. Role of endogenous angiotensin II in the increased expression of growth factors in vascular smooth muscle cells from spontaneously hypertensive rats. J Cardiovasc Pharmacol 2001; 37: 108-18
22. Tomita H, Egashira K, Ohara Y, et al. Early induction of transforming growth factor-β via angiotensin II type 1 receptors contributes to cardiac fibrosis induced by long-term blockade of nitric oxide synthesis in rats. Hypertension 1998; 32: 273-9
23. El-Agroudy AE, Hassan NA, Foda MA, et al. Effect of angiotensin II receptor blocker on plasma levels of TGF-β1 and interstitial fibrosis in hypertensive kidney transplant patients. Am J Nephrol 2003; 23: 300-6
24. Campistol JM, Iñigo P, Jimenez W, et al. Losartan decreases plasma levels of TGF-β1 in transplant patients with chronic allograft nephropathy. Kidney Int 1999; 56: 714-9
25. Porreca E, Febbo CD, Baccante G, et al. Increased transforming growth factor-beta1 circulating levels and production in human monocytes after 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibition with pravastatin. J Am Coll Cardiol 2002; 39: 1752-7
26. Sales VL, Sukhova GK, Lopez-Ilasaca AL, et al. Angiotensin type 2 receptor is expressed in murine atherosclerotic lesions and modulates lesion evolution. Circulation 2005; 112: 3328-36
27. The RESOLVD pilot study investigators. Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) pilot study. Circulation 1999; 100: 1056-64
28. Kurosaki K, Ikeda U, Murakami Y, et al. Inhibition of the renin-angiotensin system: no effect on circulating macrophage colony-stimulating factor levels in acute myocardial infarction. J Cardiovasc Pharmacol 2003; 42: 37-41
29. Erren M, Reinecke H, Junker R, et al. Systemic inflammatory parameters in patients with atherosclerosis of the coronary and peripheral arteries. Arterioscler Thromb Vasc Biol 1999; 19: 2355-63
30. Grainger DJ, Kemp PR, Metcalfe JC, et al. The serum concentration of active transforming growth factor-β is severely depressed in advanced atherosclerosis. Nat Med 1995; 1: 74-9
31. Wang XL, Liu SX, Wilcken DEL. Circulating transforming growth factor β 1 and coronary artery disease. Cardiovasc Res 1997; 34: 404-10
32. Yokota M, Ichihara S, Lin TL, et al. Association of a T29 C polymorphism of the transforming growth factor-β 1 gene with genetic susceptibility to myocardial infarction in Japanese. Circulation 2000; 101: 2783-7
33. Wikstrand J, Berglund G, Hedblad B, et al. Antiatherosclerotic effects of β-blockers. Am J Cardiol 2003; 91 Suppl.: 25-9H
34. Ohlstein EH, Douglas SA, Sung CP, et al. Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration, and neointimal formation following vascular injury. Proc Natl Acad Sci U S A 1993; 90 (13): 6189-93
35. Jinno T, Iwai M, Li Z, et al. Calcium channel blocker azelnidipine enhances vascular protective effects of AT1 receptor blocker olmesartan. Hypertension 2004; 43: 263-9
36. Nazzaro P, Manzari M, Merlo M, et al. Distinct and combined vascular effects of ACE blockade and HMG-CoA reductase inhibition in hypertensive subjects. Hypertension 1999; 33: 719-25